US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Stayble Therapeutics’ STA363 receives positive phase 1b results

Stayble Therapeutics AB ("Stayble" or the "Company") announces positive results from the Company's clinical phase 1b study in lumbar disc herniation (LDH). The study met its primary safety and tolerability endpoint. Additionally, STA363-treated patients showed a statistically significant reduction in disc volume compared to placebo-treated patients.The study met its primary endpoint with an established favorable safety profile. Only a few adverse events (AE) and no sustained serious adverse events (SAE) related to STA363 were recorded during the study. Data show a statistically

The European Patent Office announces its Intention to grant Stayble’s patent for the treatment of disc herniation

Stayble Therapeutics AB (“Stayble” or “the Company”) announced today that the European Patent Office (EPO) has issued an "Intention to Grant" for the Company’s patent for the treatment of disc herniation with STA363. "Intention to Grant" means that only a formal process remains before Stayble can receive approved patents in countries affiliated with the EPO.The patent, titled "A composition for use in the treatment of intervertebral disc herniation," was filed at the end of 2020 and provides IP protection until 2040. Additionally, there is the possibility of applying for a five-year patent

The last patient visit was completed in Stayble Therapeutics' herniated disc study

Stayble Therapeutics AB ("Stayble" or "the Company") announced today that the last patient visit has been completed in the phase 1b study involving patients with pain caused by herniated discs. This company follows the previously communicated timeline and expects to present results during the fourth quarter of 2024.A total of 25 patients were included, and 22 completed their 6-month follow-up, meaning the goal of having at least 18 evaluable patients in the study has been achieved.   CEO Andreas Gerward commented: "I am very proud that we have conducted our clinical study according

Stayble receives its first approved patent for the treatment of herniated discs

Stayble Therapeutics AB ("Stayble" or "the Company") announced today that the South African patent office, as the first country, has approved the Company's patent for the treatment of herniated discs with STA363. This approval is a significant milestone for the Company and follows a previous positive international search report from European authorities. With these advancements, we see strong potential to obtain several additional national patent approvals.The patent, titled "A composition for use in the treatment of intervertebral disc herniation," was filed at the end of 2020 and provides

Stayble Therapeutics publishes half-year report for 2024

Stayble Therapeutics AB (“Stayble” or the “Company”) hereby publishes its half-year report for 2024. The report is available as an attached document and on the Company’s website: https://staybletherapeutics.com/investor-relations/financial-reports/. Below is a summary of the report.Summary   Highlights during the second quarter (April – June 2024) · In April, it was announced that the Company's scientific abstract regarding the treatment concept for herniated discs has been accepted for a poster presentation at the International Society for the Study of the Lumbar Spine (ISSLS)

Stayble Therapeutics appoints new CFO

Stayble Therapeutics AB announces that Erik Kullgren has been appointed as the new CFO, effective August 1, 2024.Erik Kullgren has an MBA from the School of Economics at the University of Gothenburg and has extensive experience as a CFO for both listed and unlisted companies. He has also been CEO of Reguity Group AB and Dunross & Co AB. Erik Kullgren currently runs his own consulting company where he acts as CFO for, among others, Alzinova AB and Shortcut Media Group.   We welcome Erik as the new CFO of Stayble and look forward to working together. With his solid experience and

Stayble Therapeutics presents positive interim data from the ongoing phase Ib study with STA363

Stayble Therapeutics AB ("Stayble" or the "Company") announces today that the Company's phase Ib study has reached the follow-up goal of at least 18 patients completing their three-month visit. A total of 24 patients completed the visit. All essential data for evaluating the study's primary parameters have thus been secured. The company also presents positive interim data with established safety and tolerability (primary study objective) when evaluating available blinded data from the three-month follow-up. The patients will be followed until they complete their six-month visit. Then, the

(SV) Stayble Therapeutics AB (publ) offentliggör utfall i riktad emission av units

EJ FÖR PUBLICERING, DISTRIBUTION ELLER OFFENTLIGGÖRANDE, DIREKT ELLER INDIREKT, HELT ELLER DELVIS, INOM ELLER TILL USA, AUSTRALIEN, HONGKONG, JAPAN, KANADA, NYA ZEELAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, SYDKOREA, RYSSLAND, BELARUS ELLER NÅGON ANNAN JURISDIKTION DÄR SÅDAN PUBLICERING, DISTRIBUTION ELLER OFFENTLIGGÖRANDE SKULLE VARA I STRID MED GÄLLANDE REGLER ELLER KRÄVA YTTERLIGARE REGISTRERING ELLER ANDRA ÅTGÄRDER ÄN VAD SOM FÖLJER AV SVENSK RÄTT. DETTA PRESSMEDDELANDE UTGÖR INTE ETT ERBJUDANDE ATT FÖRVÄRVA VÄRDEPAPPER I STAYBLE THERAPEUTICS AB (PUBL). SE ÄVEN AVSNITTET ”VIKTIG INFORMATION”

(SV) Stayble Therapeutics AB (publ) genomför en riktad emission av units om totalt cirka tre miljoner kronor inför kommande resultat från fas 1b-studien

EJ FÖR PUBLICERING, DISTRIBUTION ELLER OFFENTLIGGÖRANDE, DIREKT ELLER INDIREKT, HELT ELLER DELVIS, INOM ELLER TILL USA, AUSTRALIEN, HONGKONG, JAPAN, KANADA, NYA ZEELAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, SYDKOREA, RYSSLAND, BELARUS ELLER NÅGON ANNAN JURISDIKTION DÄR SÅDAN PUBLICERING, DISTRIBUTION ELLER OFFENTLIGGÖRANDE SKULLE VARA I STRID MED GÄLLANDE REGLER ELLER KRÄVA YTTERLIGARE REGISTRERING ELLER ANDRA ÅTGÄRDER ÄN VAD SOM FÖLJER AV SVENSK RÄTT. DETTA PRESSMEDDELANDE UTGÖR INTE ETT ERBJUDANDE ATT FÖRVÄRVA VÄRDEPAPPER I STAYBLE THERAPEUTICS AB (PUBL). SE ÄVEN AVSNITTET ”VIKTIG INFORMATION”

Stayble Therapeutics publishes interim report for the first quarter of 2024

Stayble Therapeutics AB (“Stayble” or the “Company”) hereby publishes its interim report for the first quarter of 2024. The report is available as an attached document and on the Company’s website, https://staybletherapeutics.com/investor-relations/financial-reports/. Below is a summary of the report.Summary   Highlights during the first quarter (January – March 2024) · In January, the final data analysis of the phase IIb study with STA363 against degenerative disc disease was announced. Consistent with the preliminary topline analysis communicated in November 2023, the subgroup

(SV) Kommuniké från årsstämman i Stayble Therapeutics

Stayble Therapeutics AB, org.nr 559024-8372 ("Bolaget"), har hållit årsstämma den 15 maj 2024 kl. 13.00 på Bolagets kontor på Lennart Torstenssonsgatan 8 i Göteborg. Vid stämman fattades beslut om, bland annat, nedanstående.Fastställande av räkenskapernaÅrsstämman fastställde resultat- och balansräkningen för Bolaget för 2023. Styrelsens ledamöter och verkställande direktören beviljades ansvarsfrihet för räkenskapsåret 2023. ResultatdispositionÅrsstämman beslutade, i enlighet med styrelsens förslag, att årets resultat ska balanseras i ny räkning. Styrelse och revisorerÅrsstämman

(SV) Stayble Therapeutics publicerar årsredovisningen för 2023

Stayble Therapeutics AB (”Stayble” eller ”Bolaget”) publicerar idag årsredovisningen för 2023. Årsredovisningen finns tillgänglig på bolagets hemsida och bifogad i detta utskick.Staybles årsredovisning för 2023 finns nu tillgänglig på bolagets hemsida och kan även distribueras i tryckt format till aktieägare som så önskar.   For more information Andreas Gerward, CEO of Stayble Therapeutics AB Mail: andreas.gerward@stayble.se Phone:

(SV) Kallelse till årsstämma i Stayble Therapeutics AB

Aktieägarna i Stayble Therapeutics AB, org.nr 559024-8372, kallas till årsstämma den 15 maj 2024 kl. 13.00 på bolagets kontor på Lennart Torstenssonsgatan 8 i Göteborg. Inregistrering till årsstämman påbörjas kl. 12.30.Rätt att delta och anmälan Den som önskar delta på bolagsstämman ska: · dels vara införd i den av Euroclear Sweden AB förda aktieboken den 6 maj 2024; · dels senast den 8 maj 2024 anmäla sin avsikt att delta i årsstämman till Stayble Therapeutics AB, ”Årsstämma”, Lennart Torstenssonsgatan 8, 412 56 Göteborg, eller via e-post andreas.gerward@stayble.se.  Vid

Abstract on STA363's clinical effect on disc volume has been accepted for presentation at an important congress

Stayble Therapeutics AB ("Stayble" or the "Company") announces that the Company's scientific abstract regarding the treatment concept for herniated discs has been accepted for a poster presentation at the International Society for the Study of the Lumbar Spine (ISSLS) annual meeting in Milan, Italy, on 27-31 May 2024.The poster presents the STA363 results on lumbar discs from the phase 2b study in degenerative disc disease (DDD) and explains why STA363 can have a treatment effect in patients with herniated discs. The result demonstrates a statistically significant reduction in both disc

All patients included in Stayble Therapeutics' phase Ib study in disc hernia with STA363

Stayble Therapeutics AB ("Stayble" or the "Company") announces today that the last patient has been included in the ongoing phase Ib clinical study with STA363 towards disc hernia. No significant side effects have so far been reported and currently, none of the included patients has discontinued their participation in the study. Results from the study are expected to be available in Q4 2024.The ongoing clinical trial, conducted in collaboration with the contract research company CromSource and at four clinics in Poland, is a double-blind, placebo-controlled trial aimed primarily at studying

Stayble Therapeutics publishes year-end report for 2023

Stayble Therapeutics AB (“Stayble” or the “Company”) hereby publishes its year-end report for 2023. The report is available as an attached document and on the Company’s website, https://staybletherapeutics.com/investor-relations/financial-reports/. Below is a summary of the report.Summary   Highlights during the fourth quarter (October – December 2023) · In November, top-line data from the phase IIb study with STA363 against chronic disc-related back pain was announced. The randomized, double-blind study did not achieve the primary objective. According to the pre-specified

Stayble's CEO to BioStock: "We are looking forward to new study results in 2024"

Stayble Therapeutics enters the new year with focus on the phase Ib study in disc herniation. Patient recruitment is ongoing at four clinics and the company's plan is to be able to present study results in 2024, without additional funding. CEO Andreas Gerward tells us more in an interview.Read the full article at biostock.se : https://www.biostock.se/en/2024/01/staybles-ceo-we-are-looking-forward-to-new-study-results-in-2024/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Stayble Therapeutics presents the final data from the phase IIb study

Stayble Therapeutics AB ("Stayble" or the "Company") today presents the final data analysis of the Company's phase IIb study with STA363 against chronic disc-related back pain (degenerative disc disease, “DDD”). Consistent with the preliminary topline analysis communicated in a previous press release, the subgroup analyses verify previously announced results where no difference in pain between placebo and active groups could be detected. In patients who received the higher dose of STA363, a statistically significant difference in disc intensity was observed and in both active doses a

BioStock: Stayble’s new analyses of phase IIb study strengthen disc herniation project

Earlier this autumn, Stayble Therapeutics announced that the drug candidate STA363 had not met the primary endpoint in the phase IIb study in patients with degenerative disc disease. Now, however, additional analyses from the study are presented that may prove to have a bearing on the company’s other project regarding herniated discs. BioStock reached out to CEO Andreas Gerward to find out more.Read the full article at biostock.se : https://www.biostock.se/en/2023/12/staybles-new-analyses-of-phase-iib-study-strengthen-disc-herniation-project/ This is a

Stayble Therapeutics Phase IIb data support effectiveness in treating herniated discs

Stayble Therapeutics AB ("Stayble" or the "Company") today presents further analyses from the Phase IIb study on degenerative disc disease (DDD) and its impact on the Company's other project on lumbar disc herniation (LDH). In patients who received the higher dose of STA363, a statistically significant difference was observed in disc intensity and disc height, which are clear signs of reduced disc volume. These effects should lead to a decrease in the volume of the herniation and, thus, pain reduction in patients with herniated discs.In the ongoing analyses of results from the DDD study, a

BioStock: Stayble Therapeutics shifts focus to phase Ib study in disc herniation

Following dissapointing results from the phase IIb study, Stayble Therapeutics is shifting its focus to the phase Ib study in hearniated disc patients. At the same time, the company plans to reduce costs in order to complete the study without additional funding. CEO Andreas Gerward shares more details in an interview with BioStock.Read the full article at biostock.se: https://www.biostock.se/en/2023/11/stayble-therapeutics-shifts-focus-to-phase-ib-study-in-disc-herniation/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Correction: Stayble Therapeutics publishes interim report for the third quarter of 2023

Republishes with MAR text in the press release. No changes have been made to the press release or the attached report. Stayble Therapeutics AB ("Stayble" or the "Company") hereby publishes its quarterly report for the third quarter of 2023. The report is available as an attached document and on the Company's website, www.staybletherapeutics.com/en/investors/financial-reports/. Below is a summary of the report.Summary   Highlights during the third quarter (July – September 2023) · In July, Stayble announced that about 90% of the patients in the ongoing Phase IIb study for

Stayble Therapeutics publishes interim report for the third quarter of 2023

Stayble Therapeutics AB ("Stayble" or the "Company") hereby publishes its quarterly report for the third quarter of 2023. The report is available as an attached document and on the Company's website, www.staybletherapeutics.com/en/investors/financial-reports/. Below is a summary of the report.Summary   Highlights during the third quarter (July – September 2023) · In July, Stayble announced that about 90% of the patients in the ongoing Phase IIb study for treating degenerative disc diseases have completed their twelve-month follow-up. · In August, the first patient was included

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe